



FOR IMMEDIATE RELEASE

Contact:

Karin Hehenberger, M.D., Ph.D.
Senior Director of Scientific and External Affairs
Office: 212 824 3176
Facsimile: 212 824 3240
Email: karin.hehenberger@eyetech.com
www.eyetech.com

**Eyetech Pharmaceuticals, Inc. to Host Live Discussion of FDA Approval
of Macugen® (pegaptanib sodium injection)**

New York, NY - December 17, 2004 – Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET) today announced that it will host a live discussion by Eyetech management regarding the approval by the United States Food and Drug Administration of the use of Macugen®(pegaptanib sodium injection) in the treatment of neovascular (wet) age-related macular degeneration.

Live audio of the conference call will be available to investors, members of the news media and the general public on Monday, December 20 at 8:30AM, before the US markets open by dialing 888-275-0218 (in the United States) or 706-679-7756 (internationally). A playback of this event will be available through January 3, 2005 by dialing 800-642-1687 (within the United States) or 706-645-9291 (internationally). The passcode for this replay will be 2770157. In addition, this discussion will be broadcasted simultaneously over the Internet and the webcast can be accessed by logging on to the Investor Relations section of our corporate website at www.eyetech.com. An archived version of the webcast will be available at the same location through January 3, 2005.

About Eyetech Pharmaceuticals, Inc.

Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen® (pegaptanib sodium injection) with

Pfizer Inc for the treatment of neovascular AMD. Macugen is also being studied for the treatment of diabetic macular edema and retinal vein occlusion.

###